Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Tremelimumab + FOLFOX in Metastatic Colorectal Cancer
NCT03202758Phase 2Completed
- Sponsor
- Centre Georges-François Leclerc
- Start
- Aug 2017
- Primary completion
- Jan 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and tremelimumab in colorectal cancer (CRC), sponsored by Centre Georges-François Leclerc. Primary endpoints: Safety of Durvalumab plus Tremelimumab in combination with FOLFOX at 1 month and Progression Free Survival. Started Aug 2017; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03202758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03202758.